From the Journals

Dupilumab Faces Trial in Chronic Hives

Phase III CUPID-C trial evaluates biologic therapy in patients with chronic spontaneous urticaria uncontrolled by antihistamines.

Share

  • 1

    Dupilumab reduces itch severity in chronic spontaneous urticaria (CSU).

  • 2

    The trial involved 151 patients across nine countries.

  • 3

    Significant symptom reduction was observed at week

  • 4

    Safety outcomes were similar between dupilumab and placebo groups.

  • 5

    41% of patients on dupilumab achieved well-controlled disease.

  • 6

    Dupilumab blocks IL-4 and IL-13 signaling pathways.

  • 7

    The study confirmed benefits of dupilumab in antihistamine-refractory CSU.

  • 8

    Study limitations include limited duration and diversity.

Original Source(s)

Dupilumab Faces Trial in Chronic Hives

  • by Kathryn Wighton

  • March 12, 2026

Related Content

HS Linked to Higher Self-Harm, Suicide Risk

Prior self-harm episodes and nonviolent methods are more common among HS patients who die by suicide, new research finds.

Dual-Frequency Radiofrequency for Facial Laxity?

Investigators report high 90-day response rates with no persistent adverse events.

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.